SCHEMBL7876691

SCHEMBL7876691

NC(=O)C(=O)N(N)c1cccc(O)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
TSHR P16473 1/20 0.47
PARP1 P09874 1/20 0.46
CYP3A4 P08684 3/20 0.43
CA12 O43570 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
CA14 Q9ULX7 2/20 0.39
LMNA P02545 2/20 0.39
CA5A P35218 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
CA1 P00915 2/20 0.38
CA6 P23280 1/20 0.38
KDM4E B2RXH2 2/20 0.38
CA7 P43166 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HSD17B1 P14061 4/20 0.37
HSD17B2 P37059 4/20 0.37
EGLN2 Q96KS0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30305207 0.85 ALDH1A1 (0.50) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL26105069 0.85 ALDH1A1 (0.50) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL28723709 0.80 ALDH1A1 (0.55) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL10783514 0.78 NPSR1 (0.50) ALDH1A1TSHRPARP1CYP3A4LMNA
SCHEMBL27601452 0.76 ALDH1A1 (0.49) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL8057668 0.75 CA12 (0.48) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL7872338 0.75 TSHR (0.53) ALDH1A1TSHRLMNAKDM4EKMT2A
SCHEMBL11804404 0.75 ALDH1A1 (0.52) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL214884 0.72 ALDH1A1 (0.59) ALDH1A1TSHRPARP1CYP3A4CA12
SCHEMBL28135524 0.71 MEN1 (0.41) ALDH1A1TSHRPARP1CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6331555-B1 EVALUATING SUSCEPTIBILITY OF CANCER TO COMPOUNDS WHICH INHIBIT PLATELET DERIVED GROWTH FACTOR RECEPTOR ACTIVITY UNIVERSITY OF CALIFORNIA 2001-12-18 US disclosed
EP-1000617-A2 Treatment of platelet derived growth factor related disorders such as cancers using inhibitors of platelet derived growth receptor Sugen, Inc. (US) 2000-05-17 EP disclosed
US-5990141-A ADMINISTERING 5-METHYL-ISOXAZOLE-4-CARBOXYLIC ACID-N-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-TRIFLUORO-METHYL)PHENYL-2-BUTENAMIDE; ANTITUMOR,-CARCINOGENIC AND PROLIFERATIVE AGENTS; KINASE INHIBITORS SUGEN INC. (US) 1999-11-23 US disclosed
US-5958959-A ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)ANILIDE OR 2-CYANO-3-HYDROXY-N-(4-(TRIFLUOROMETHYL)PHENYL)-2-BUTENAMIDE SUGEN, INC. (US) 1999-09-28 US disclosed
US-5932602-A ANTIGROWTH AGENTS; ANTITUMOR AGENT; USING AN ISOOXIDAZOLE COMPOUND SUGEN, INC. (US) 1999-08-03 US disclosed
US-5700822-A ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF ISOXAZOLE AMIDE DERIVATIOVE AND CYANO, HYDROXY, AROMATIC AMIDE DERIVATIVE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-12-23 US disclosed
US-5700823-A ADMINISTERING 5-METHYLISOXAZOLE-4-CARBOXYLIC ACID-(4-TRIFLUOROMETHYL)-ANILIDE OR N-(4-TRIFLUOROMETHYLPHENYL)-2-CYANO-3-HYDROXYCROTONAMIDE SUGEN, INC. (US) 1997-12-23 US disclosed
EP-0804191-A1 TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR Sugen, Inc. (US) 1997-11-05 EP disclosed
WO-1995019169-A2 TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR SUGEN, INC. (US) 1995-07-20 WO disclosed